{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:43Z","timestamp":1791655543591,"version":"4.3.4"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1097\/01.cad.0000203385.45163.76","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T04:01:57Z","timestamp":1142827317000},"page":"423-427","source":"Crossref","is-referenced-by-count":24,"title":["Aspirin reduces adverse effects of gefitinib"],"prefix":"10.1097","volume":"17","author":[{"given":"Shigenori","family":"Kanazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shosaku","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1160\/TH04-02-0127","article-title":"Aspirin and coronary artery disease","volume":"92","author":"Maree","year":"2004","journal-title":"Thromb Haemost"},{"key":"R2-8-20210203","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0163-7258(98)00045-X","article-title":"The epidermal growth factor receptor and its inhibition in cancer therapy","volume":"82","author":"Woodburn","year":"1999","journal-title":"Pharmacol Ther"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0169-5002(03)00043-6","article-title":"Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer","volume":"40","author":"Okamoto","year":"2003","journal-title":"Lung Cancer"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2005.05.148","article-title":"Gefitinib has the potential of activating cell immunity against malignant cells","volume":"23","author":"Kanazawa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R8-8-20210203","first-page":"244s","article-title":"Elevation of plasma RANTES levels and prognosis in patients treated with gefitinib","volume":"23","author":"Yamaguchi","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1357-2725(99)00015-1","article-title":"Molecules in focus EGFR receptor","volume":"31","author":"Wells","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2004.99.337","article-title":"Molecular markers to predict response to gefitinib: EGFR, ErbB2, or more?","volume":"22","author":"Normanno","year":"2004","journal-title":"J Clin Oncol"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/107602960501100409","article-title":"Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance","volume":"11","author":"Kanazawa","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1084\/jem.176.2.587","article-title":"Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils","volume":"176","author":"Kameyoshi","year":"1992","journal-title":"J Exp Med"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007632-200601010-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:23:02Z","timestamp":1785856982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200604000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cad.0000203385.45163.76","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}